FENNEC PHARMACEUTICALS INC. 8-K

What Happened Fennec Pharmaceuticals Inc. filed an 8‑K reporting that director Rostislav Raykov notified the company on April 27, 2026 that he will retire and will not stand for re‑election at the company's 2026 annual meeting of shareholders. Mr. Raykov’s current term will expire immediately following the 2026 annual meeting. The filing states his departure is not due to any disagreement with the company on operations, policies or practices.

Key Details

• Notifying date: April 27, 2026 (8‑K filed April 28, 2026).
• Director: Rostislav Raykov will not stand for re‑election; term ends immediately after the 2026 annual meeting.
• Board size change: Board will be reduced from six directors to five effective immediately following the annual meeting.
• Vacancies: Company expects no vacancies on the Board after Mr. Raykov’s departure.

Why It Matters This is a governance change that alters board composition but, per the filing, does not reflect any disagreement with management. For investors, the change could affect board committees and oversight dynamics, but the company expects no vacancy and has already decided to reduce the board size — suggesting a planned, orderly transition rather than an unexpected departure. Retail investors may watch upcoming proxy materials and the annual meeting for any additional board or governance details.